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ABSTRACT 22 
Dengue is a global public health concern and this is aggravated by a lack of vaccines or 23 
antiviral therapies. Despite the well-known role of CD8+ T cells in the immunopathogenesis of 24 
Dengue virus (DENV), only recent studies have highlighted the importance of this arm of the 25 
immune response in protection against the disease. Thus, the majority of DENV vaccine 26 
candidates are designed to achieve protective titers of neutralizing antibodies, with less 27 
regard for cellular responses. Here, we used a mouse model to investigate CD8+ T cell and 28 
humoral responses to a set of potential DENV vaccines based on recombinant modified 29 
vaccinia virus Ankara (rMVA). To enable this study, we identified two CD8+ T cell epitopes in 30 
the DENV-3 E protein in C57BL/6 mice. Using these we found that all the rMVA vaccines 31 
elicited DENV-specific CD8+ T cells that were cytotoxic in vivo and polyfunctional in vitro. 32 
Moreover, vaccines expressing the E protein with an intact signal peptide sequence elicited 33 
more DENV-specific CD8+ T cells than those expressing E proteins in the cytoplasm. 34 
Significantly, it was these same ER-targeted E protein vaccines that elicited antibody 35 
responses. Our results support the further development of rMVA vaccines expressing DENV 36 
E proteins and add to the tools available for dengue vaccine development. 37 
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INTRODUCTION 44 
It is estimated that 3.6 billion people living in 124 tropical and subtropical countries are at risk 45 
of dengue virus (DENV) infections [1, 2]. Recent evaluations suggested that more than 390 46 
million individuals are infected every year and, of these, 96 million seek medical attention [3]. 47 
DENV belongs to the Flaviviridae family and has four distinct serotypes: DENV-1, DENV-2, 48 
DENV-3, and DENV-4. Infection with one serotype provides life-long protection against re-49 
infection by the same serotype, but only a short-term protection against the 3 heterologous 50 
types. The DENV E glycoprotein is a surface protein and has functions that include cell 51 
receptor binding and fusion with host cell membranes during penetration. Importantly, E is an 52 
immunodominant protein that harbors many antigenic determinants known to elicit protective 53 
immune responses [4, 5]. 54 
At present effective vaccines against dengue are not available. Several candidate 55 
vaccines have been developed and are currently being evaluated in preclinical and clinical 56 
trials [6, 7, 8]. One of the leading candidates is the Sanofi Pasteur CYD vaccine, a tetravalent 57 
live chimeric vaccine based on the 17D attenuated yellow fever virus backbone. However, 58 
despite excellent safety and immunogenicity profiles, the efficacy of this vaccine in phase 2b 59 
tests did not meet the expected threshold [9, 10]. In light of this, it is prudent to maintain a 60 
diverse pipeline of DENV vaccine candidates. Modified Vaccinia Ankara (MVA) has been 61 
shown to be a highly immunogenic recombinant vaccine vector in a number of settings, 62 
inducing good antigen-specific antibody and CD8+ T cell responses [11, 12, 13, 14, 15]. 63 
Further, previous work has suggested that mucosal delivery of MVA-based vaccines can 64 
circumvent the problem of pre-existing immunity to the vector [16]. 65 
Here we present a set of MVA-vectored dengue vaccines and establish a model in 66 
C57BL/6 mice to explore their immunogenicity both for CD8+ T cells and antibodies. 67 
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 68 
MATERIALS AND METHODS 69 
Viruses and cells  70 
Primary chicken embryo fibroblasts (CEF) were prepared as described [17] and grown in 71 
Dulbecco’s Modified Eagle medium (DMEM) supplemented with 2 mM L-glutamine and 10% 72 
fetal bovine serum (FBS). BHK-21 cells were grown in Minimal Essential medium (MEM) 73 
supplemented with 2 mM L-glutamine and 10% FBS. Vaccinia virus (VACV) strain MVA, and 74 
DENV-3 were gifts from Bernard Moss (NIH, Bethesda) and John Aaskov (IHBI, Brisbane), 75 
respectively.  76 
Recombinant viruses  77 
Recombinant MVAs (rMVA/E, rMVA/EM, rMVA/Sg-E and rMVA/Sg-EM) expressing a C-78 
terminally truncated DENV-3 E protein were generated by homologous recombination in CEF 79 
cells (Supplementary Fig. 1). The rMVA/E and rMVA/EM contain the DNA sequence for 80% 80 
of the E glycoprotein gene (polyprotein amino acids 281 – 675), and the rMVA/Sg-E and 81 
rMVA/Sg-EM contain the same E sequence preceded by the predicted N-terminal E signal 82 
peptide (polyprotein amino acids 266 – 675).  The relevant sequences were amplified by RT-83 
PCR from a DENV-3 genotype III clinical isolate (GenBank accession # FJ850094) using the 84 
following primers: 85 
AAACCCGGGACCATGGTGGTTATTTTTATACTACTAATGCTGGTCACCCCATCC, 86 
AAACCCGGGACCATGAGATGTGTGGGAGTAGGAAACAGAGATTTTGTGGAAGG (forward 87 
primers) and 88 
TTTCTGCAGACAAAAAACATCTTCCCTTAGGAGCTTCCTTTCTTATACCAGTTG (reverse 89 
primer). Viruses rMVA/EM and rMVA/Sg-EM also have an internally located Kozak sequence 90 
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eliminated through use of the QuikChange Site-Directed Mutagenesis Kit (Stratagene). 91 
Primers CGGAGGGTGTGTGACTTCGATGGCTAAGAACAAGC and 92 
GCTTGTTCTTAGCCATCGAAGTCACACACCCTCCG were used for mutagenesis. The PCR 93 
products were inserted into the SmaI and PstI sites of pLW44 plasmid (provided by Bernard 94 
Moss) [18] to create transfer plasmids. Plasmid pLW44 contains homologous sequences 95 
flanking the Deletion III region of MVA genome and green fluorescent protein (GFP) under the 96 
p11 late promoter. Exogenous gene expression is controlled by the strong mH5 promoter, a 97 
late/early promoter. Transfer plasmids were sequenced and used to generate the 98 
recombinant MVAs. To this end, plasmids were transfected into CEF cells previously infected 99 
with MVA and, after 2 days, the recombinant MVAs were picked. Selection of recombinants 100 
was ensured through six successive rounds of plaque purification using the visual aid of GFP 101 
expression. MVAs were grown in BHK-21 and purified by centrifugation through a 36% 102 
sucrose cushion before titration in BHK-21 cells. Expression of the various E protein variants 103 
in infected cells was tested by western-blotting (Supplementary Fig.1C). Cells were infected at 104 
MOI of 1 and after 24 hours lysates in electrophoresis loading buffer (240 mM Tris-HCl pH 105 
6,8; 40% glycerol; 0,8% SDS; 0,02% bromophenol blue; β-mercaptoethanol 200 mM) were 106 
obtained. Proteins were electrophoresed and blotted onto PVDF membranes (GE Healthcare, 107 
HybondTM-P). Proteins were probed using mouse anti-DENV 1+2+3+4  (ab9202, Abcam®) 108 
and rabbit anti-mouse IgG HRP (A9044, SIGMA) as secondary antibody. Blots were revealed 109 
using ECLTM Plus Western Blotting Detection System (GE Healthcare) and Amersham 110 
Hyperfilm ECL (GE Healthcare). 111 
Synthetic peptides 112 
Putative CD8+ T cell epitopes for DENV-3 E protein binding to H-2d and H-2b MHC I 113 
molecules were predicted as described in results. Control peptides used were: MVA A3270, 114 
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KSYNYMLL [19] and herpes simplex virus gB452, YQPLLSNTL [20]. Synthetic peptides were 115 
purchased from Mimotopes (Clayton, Australia), stocks at 10 mg/ml in dimethylsulfoxide 116 
(DMSO) were diluted to the desired concentration in serum-free DMEM.  117 
Mice and infections 118 
Female BALB/c, C57BL/6, and C57BL/6.SJL mice, older than 8 weeks, were obtained from 119 
the ANU Bioscience Resource Facility. For cellular analysis, mice were immunized 120 
intraperitoneally (i.p.) with 1 × 106 PFU of recombinant MVA in 200 µl of PBS. Alternatively 121 
mice were infected i.p. with 200 µl of DENV-3 (D94.283) [21]. To analyze humoral responses, 122 
mice were immunized intradermally (i.d.) [22] using two doses, 28 days apart, with each  123 
containing 107 PFU of MVA or 10 µg recombinant E protein plus adjuvant (saponin, Sigma) in 124 
10 µl of PBS.  All animal procedures were conducted in compliance with ethical requirements 125 
and approved by the Australian National University (ANU) Animal Ethics and Experimentation 126 
Committee.  127 
Peptide stimulation and intracellular cytokine staining (ICS) of IFN- γ and TNF-α 128 
Mice were euthanized 7 or 42 days after immunization and spleens were taken for analysis of 129 
CD8+ T cell responses by ICS [23]. Briefly, 1×106 splenocytes were incubated with peptides 130 
(10-5 to 10-12 M final) at 37°C with 5% CO2. After 1h, 1 µg of Brefeldin A (Sigma) was added to 131 
each well and plates were incubated for another 3h. Cells were then stained for surface CD8 132 
(clone 53-6.7, BioLegend) before fixing and stained for intracellular cytokines (anti-IFN-γ-133 
APC, clone XMG1.2; anti-TNF-α-PE-Cy7 clone MP6-XT22) in the presence of 0.5% saponin 134 
(Sigma). Results were acquired using a FACS LSR II (BD Biosciences) and analyzed with 135 
Flowjo software (Tree Star Inc.). Backgrounds were determined by using control wells with no 136 
peptides for each mouse and were subtracted from the values of test samples. 137 
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Staining of CD107a/b 138 
Splenocytes were incubated with peptides as above but with the addition of Golgi-Stop (BD 139 
Biosciences) and anti-CD107a/b-FITC. After this incubation, cells were stained for surface 140 
CD8 and intracellular IFN-γ. Acquisition, analysis and subtraction of background were as 141 
described above. 142 
In vivo cytotoxicity assay 143 
Splenocytes from C57BL/6.SJL (CD45.1+) mice were pulsed 10-6 M peptide for use as 144 
targets. Three treatments of these were done with different peptides and amounts of CFSE 145 
label: 1) gB452, as an irrelevant peptide and  5 µM CFSE; 2) D3E284-292 and 0.5 µM CFSE; 3) 146 
D3E408-415 and no CFSE. These cells were mixed in equal proportion and a total of 5×106 147 
injected by intravenous (i.v.) injection into C57BL/6 mice 7 days after immunization. Mice 148 
were euthanized after 22 h and the recovery of each of the cell populations described above 149 
determined by flow cytometry. The following formula was used to determine specific lysis. 150 
Ratio = (percentage CFSEhigh/ percentage CFSElow) for D3E284-292 or ratio = (percentage 151 
CFSEhigh/ percentage CFSEneg) for D3E408-415. Percent specific lysis = [1 – (ratio naïve mouse 152 
/ ratio infected mouse) x 100]. 153 
ELISA 154 
Serum was taken 14 days after the final immunization and tested in duplicate for anti-E IgG 155 
antibodies. Nunc Maxisorp® plates were coated overnight with recombinant DENV-3 E protein 156 
(100 ng/well) in bicarbonate buffer. After blocking for 2 hours with 5% skim milk in PBS-T, 157 
diluted serum samples (1/100) were added to the plates and incubated for 1 hour at room 158 
temperature. Bound antibody was detected with anti-mouse IgG-HRP (1:10000) (#7076, Cell 159 
Signaling) and TMB substrate at 100 µl/well. Absorbance at 450 nm was then measured. 160 
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Statistical analysis 161 
Comparisons were made using one-way ANOVA followed by post analysis with Bonferroni’s 162 
multiple comparison tests (GraphPad Prism v5.00). Differences were considered significant 163 
when p ≤ 0.05. 164 
 165 
RESULTS 166 
Identification of CD8+ T cell epitopes in DENV-3 E 167 
 To enable comparison of DENV-3 E-specific CD8+ T cell responses in a mouse model, we 168 
first needed to identify H-2-restricted epitopes in this protein. Some progress has been made 169 
in identifying DENV-specific CD8+ T cell epitopes, but most are in non-structural proteins and 170 
restricted to human MHC alleles [24, 25, 26]. Epitope identification work in mice has focused 171 
largely on DENV-2 [27, 28]. For the DENV-3 E protein, several CD8+ T cell epitopes have 172 
been predicted, but only one has been shown to be immunogenic in DENV infection [29, 30, 173 
31]. We predicted H-2d- and H-2b-binding peptides from the DENV-3 E protein sequence 174 
(FJ850094) combining results from BIMAS, IEDB and SYFPEITHI databases [32, 33, 34]. 175 
From these predictions, thirteen peptides were synthesized, in each case we used only the 176 
longest version of any predicted binding sequence irrespective of rank (Table 1). 177 
Next, the peptides were used to restimulate splenocytes taken from mice 7 days after 178 
immunization with rMVA/E (Supplementary Fig. 1) and their ability to induce IFN-γ production 179 
by CD8+ T cells detected by ICS. In C57BL/6 mice, D3E284-292 (VGVGNRDFV) and D3E408-419 180 
(KVVQYENLKYTV), stimulated IFN-γ production by CD8+ T cells (Table 1 and Figure 1A) 181 
from mice immunized with rMVA/E, but not MVA. These initial screens used 10-5 M peptide so 182 
to validate and refine our mapping they were tested at concentrations down to 10-12 M. 183 
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D3E284-292 was able to restimulate a half-maximal response at between 10-9 and 10-10 M and 184 
we concluded that this sequence was likely to be optimal (Figure 1B). However, half-maximal 185 
responses to D3E408-419 were >10-8 M (Figure 1C). To map a minimal H-2b-restricted epitope 186 
in this region, we tested a range of peptide variations at a wide range of concentrations 187 
(Figure 1D). D3E408-415 (KVVQYENL) had a half maximal response at the lowest 188 
concentration among all peptides and was chosen as the most likely minimal epitope. None of 189 
the predicted H-2d-restricted peptides were active in assays using splenocytes from 190 
immunized BALB/c mice and no further work was done in this strain. 191 
D3E284-292 and D3E408-415 are recognized by CD8+ T cells during DENV-3 infection 192 
To ensure the epitopes mapped using our vaccine were also presented during DENV 193 
infection, D3E284-292 and D3E408-415 were tested for their ability to stimulate IFN-γ production 194 
by CD8+ T cells from spleens of C57BL/6 mice infected 7 days earlier with a passage 1 stock 195 
of DENV-3 [21]. Figure 1E and 1F shows that D3E284-292 and D3E408-415 were both epitopes in 196 
the context of a DENV-3-infection. Of these, D3E284-292 (VGVGNRDFV) has been previously 197 
predicted [30], but not shown to be elicited by DENV infection and the more dominant D3E408-198 
415 is entirely novel. 199 
ER-targeted E protein is more immunogenic for CD8+ T cells 200 
We then used the epitopes to investigate whether there were differences in immunogenicity 201 
across a set of rMVA vaccines. These vaccines, namely rMVA/E, rMVA/EM, rMVA/Sg-E and 202 
rMVA/Sg-EM, all express 80% of DENV-3 E, but rMVA/Sg-E and rMVA/Sg-EM address the 203 
protein to the endoplasmic reticulum (ER) via the native signal sequence. In addition, 204 
rMVA/EM and rMVA/Sg-EM had a potential internal Kozak sequence eliminated by 205 
mutagenesis, in case this compromised translation of full length E protein. Western blotting 206 
showed that the vaccines expressed similar levels of E protein, irrespective of the design 207 
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(Supplementary Fig. 1). Groups of mice were immunized with each of the recombinant viruses 208 
and CD8+ T cell responses to the DENV-3 and several native MVA epitopes were measured 209 
at the peak of the acute response (7 days) and in memory (42 days). On day 7, there were 210 
significantly more CD8+ T cells responding to the DENV peptides when measured by 211 
detecting IFN-γ alone, IFN-γ and CD107, or IFN-γ and TNF-α in mice immunized with MVA 212 
vectors expressing ER-targeted E protein, compared to those without the signal sequence 213 
(Figure 2). However, there was no apparent advantage in mutating the internal Kozak 214 
sequence (Figure 2). 215 
For memory responses, the trend for higher responses elicited by vaccines with E 216 
proteins having signal sequences was maintained, but only reached statistical significance for 217 
D3E284-292 when measured by co-expression of intracellular IFN-γ and surface CD107 (Figure 218 
3). In all experiments responses to native MVA epitopes were similar across the vaccines (not 219 
shown). 220 
DENV-3 vaccines induce cytotoxic CD8+ T cells 221 
To ensure that our vaccines elicited DENV-3-specific cytotoxic CD8+ T cells, we assessed the 222 
ability of immunized mice to eliminate peptide loaded targets in vivo (Figure 4) [23, 35]. For 223 
this experiment we immunized mice with rMVA/Sg-E, rMVA/E or used MVA as a control and 224 
the ability of mice to kill cells loaded with D3E284-292 and D3E408-415 was tested 7 days later. As 225 
expected, control MVA-immunized mice were unable to kill either of the D3E-peptide loaded 226 
targets. Mice immunized with each of the two rMVA DENV-3 vaccines were able to kill targets 227 
loaded with either D3E284-292 or D3E408-415. There was no significant difference in killing 228 
between the vaccines, but the mean specific lysis for rMVA/Sg-E was higher for both 229 
epitopes. 230 
ER-targeted E protein generates superior antibody responses 231 
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Given the established role for antibodies in protection against DENV, it was important to 232 
determine if changing the cellular location of the E protein also altered humoral responses. To 233 
test this we immunized mice with rMVA/E, rMVA/Sg-E or controls, giving two doses of 107 234 
PFU 28 days apart and then measuring antibodies by ELISA two weeks after the boost. 235 
Whereas rMVA/Sg-E was able to induce an easily detectable antibody response, rMVA/E 236 
elicited no response distinguishable from background (Figure 5).  237 
 238 
DISCUSSION 239 
The quest for an effective dengue vaccine has recently reached a milestone with a phase 2b 240 
clinical trial of the Sanofi Pasteur CYD vaccine in Thailand. However, the overall efficacy was 241 
only 30.2% suggesting a requirement for alternative strategies [9, 10]. 242 
 Almost all neutralizing antibodies are directed against epitopes in the DENV E protein 243 
and for this reason it is an obvious choice for dengue subunit vaccines. CD8+ T cell epitopes 244 
in E are likely to be less immunodominant than others in non-structural proteins [25, 28, 29], 245 
but the renewed interest in cellular immunity suggests these should not be ignored [25, 28, 246 
36]. With this in mind we wanted to evaluate CD8+ T cell immunity to the E protein in our 247 
rMVA vectored dengue vaccines prior to testing antibody responses, but this required first 248 
identifying CD8+ T cell epitopes for DENV-3 E. Variants of D3E284-292 in other flaviviruses 249 
have previously been shown to be CD8+ T cell epitopes with some cross-reactivity across 250 
these viruses [30]. We now show that this is also an epitope of DENV-3 and responses to this 251 
peptide are also elicited by rMVA E protein vaccines. D3E408-415 is entirely novel and it is also 252 
significantly more dominant than D3E284-292. Indeed in mice immunized with rMVA vaccines, 253 
D3E408-415 was more immunogenic than the native MVA A3270-277 epitope used for 254 
comparison, which is second ranked in the MVA immunodominance hierarchy [37]. In contrast 255 
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to C57BL/6 mice, none of the predicted H-2d-binding peptides were found to be immunogenic 256 
in the context of our MVA vaccine. This may reflect the reliability of the predictive algorithms 257 
for H-2d or the relatively poor immunogenicity of MVA in BALB/c mice [38]. 258 
Our evaluation of rMVA/E vaccines demonstrates the value of CD8+ T cell epitope 259 
information in vaccine development. Here we show that a modification of the DENV-3 E 260 
protein that strongly improves humoral responses is also most likely superior for eliciting CD8+ 261 
T cells. The improvement in CD8+ T cell responses were statistically significant at acute times 262 
and in every memory experiment the mean response was higher for groups immunized with 263 
the ER-targeted E protein, even if generally not reaching significance. We speculate that this 264 
may also be the case for E proteins expressed from vectors other than MVA. 265 
Recent studies for several infectious diseases, including dengue, suggest that the 266 
quality of CD8+ T cells, as demonstrated by their ability to exert multiple functions, is important 267 
[39, 40, 41, 42, 43, 44, 45]. For example, higher frequencies of CD8+ T cells expressing TNF-268 
α, IFN-γ, and IL-2 in Thai children were associated with the development of subclinical, rather 269 
than clinical secondary infection [46]. Another study showed that higher and more 270 
polyfunctional responses in the context of particular HLA alleles were associated with a 271 
decreased susceptibility to severe disease [25]. Together these suggest that a vigorous 272 
response by multifunctional CD8+ T cells is important for protection against dengue. All rMVA 273 
vaccines evaluated here elicited responses that included co-incident production of IFN-γ and 274 
TNF-α or production of IFN-γ and degranulation . In general the ability of CD8+ T cells to 275 
produce cytokines after stimulation is in the order: IFN-γ, TNF-α and IL-2 [47]. In this context, 276 
the fraction of IFN-γ+ CD8+ T cells also making TNF-α was approximately 80% for all the 277 
vaccines, suggesting that all elicit a response of similar quality (not shown). Finally, all 278 
vaccines induced a response that was able to kill targets displaying DENV-3 E-derived 279 
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peptides in vivo. In summary, these results suggest that the CD8+ T cell response elicited by 280 
the rMVA vaccines tested here is polyfunctional and importantly this was not reduced by 281 
modifying the E protein to improve antibody responses.  282 
In conclusion, we provide new tools for pre-clinical analysis of cellular immune 283 
responses to DENV vaccines and use them to demonstrate that the requisites for a good 284 
antigen can coincide for humoral and CD8+ T cell immunity. This work adds to previous 285 
studies of an MVA vector expressing DENV proteins tested in non-human primates [48]. Our 286 
results support further development of MVA vectored dengue vaccines and show that 287 
targeting DENV E to the ER improves cellular and humoral immune responses to this 288 
important antigen. 289 
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FIGURE LEGENDS 449 
 450 
Figure 1. Mapping of CD8+ T cell epitopes in DENV-3 E glycoprotein.  Mice were 451 
immunized i.p. with MVA, rMVA/E or DENV-3 isolate D94.283 (approx. 103 PFU) and 7 days 452 
later, percentages of CD8+ T cells producing IFN-γ in response to the peptides shown were 453 
measured by ICS. (A) Representative flow cytometry plots for mice immunized with rMVA/E or 454 
MVA.  Nil, control with no peptide; A3270, native epitope of MVA. (B) Fraction of CD8+ T cells 455 
responding to D3E284-292 (VGVGNRDFV) at the indicated concentrations. (C) As for B, but 456 
using D3E408-419 (KVVQYENLKYTV). (D) Redefining the D3E408-419 peptide. Fraction of CD8+ 457 
T cells responding to the variants of D3E408-419 as shown. (E) Representative flow cytometry 458 
plots for mice immunized with DENV-3, rMVA/Gg-E or MVA. Peptides as for panel A. (F) The 459 
percent of CD8+ T cells from each immunization group producing IFN-γ after stimulation with 460 
the peptides shown. Data are the mean and SEM from a group of four DENV-3-infected mice 461 
and are individual mice for the other immunizations. Results in panel F were independently 462 
reproduced using a second isolate of DENV-3. For other panels, data are representative of 2 463 
(panels C and D) or 3 (panel B) experiments. 464 
 465 
Figure 2. Immunogenicity of rMVA/DENV-3E vaccines at acute times. C57BL/6 mice were 466 
immunized i.p. with 106 PFU of rMVA/Sg-E, rMVA/Sg-EM, rMVA/E or rMVA/EM and 7 days 467 
later, splenocytes were used in ICS assays. (A and B) Percentages of CD8+ splenocytes that 468 
produced IFN-γ after stimulation with D3E284-292 and D3E408-415 peptides, respectively. Data 469 
are represented as means and SEM from 3 experiments (C and D) Percentages of 470 
CD8+/CD107ab+ splenocytes that produced IFN-γ after stimulation with D3E284-292 and 471 
D3E408-415 peptides, respectively. Data are represented as means and SEM from 2 472 
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experiments. (E and F) Percentages of CD8+/IFN-γ+ splenocytes that produced TNF-α after 473 
stimulation with the peptides D3E284-292 and D3E408-415, respectively.  Data are represented as 474 
means and SEM from 2 experiments. Peptide concentration was 10-7 M. *, p ≤ 0,5; **, p ≤ 475 
0,01; ***, p ≤ 0,001. 476 
 477 
Figure 3. Immunogenicity of rMVA/DENV-3E vaccines in memory. C57BL/6 mice were 478 
immunized i.p. with 106 PFU of rMVA/Sg-E, rMVA/Sg-EM, rMVA/E or rMVA/EM and 42 days 479 
later, splenocytes were used in ICS assays. (A and B) Percentages of CD8+ splenocytes that 480 
produced IFN-γ after stimulation with D3E284-292 and D3E408-415 peptides, respectively. (C and 481 
D) Percentages of CD8+/CD107ab+ splenocytes that produced IFN-γ  after stimulation with 482 
D3E284-292 and D3E408-415 peptides, respectively. (E and F) Percentages of CD8+/IFN-γ+ 483 
splenocytes that produced TNF-α after stimulation with the peptides D3E284-292 and D3E408-484 
415, respectively. Peptide concentration was 10-7 M. Data are represented as means and SEM 485 
from 3 experiments. *, p ≤ 0,5; **, p ≤ 0,01; ***, p ≤ 0,001. 486 
 487 
Figure 4. Cytotoxic capacity of DENV-3E-specific CD8+ T cells. A) Specific lysis of  488 
D3E284-292 peptide loaded cells. B) Specific lysis of  D3E408-415 peptide loaded cells. Data are 489 
represented as means and SEM from 2 experiments. *, p ≤ 0,5; **, p ≤ 0,01; ***, p ≤ 0,001. 490 
 491 
Figure 5. Humoral immunogenicity for rMVA/DENV-3E vaccines. C57BL/6 mice were 492 
immunized i.d. through a homologous prime-boost protocol with 107 PFU of rMVA/Sg-E or 493 
rMVA/E and, 14 days later, serum samples were used in ELISA assays to detect anti-E IgG 494 
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antibodies. Data are represented as means and SEM from 2 experiments.  *, p ≤ 0,5; **, p ≤ 495 
0,01; ***, p ≤ 0,001. 496 
 497 
 498 
Supplementary Figure 1. Generation of recombinant MVAs expressing truncated DENV-499 
3 E glycoproteins. (A) To generate the recombinants MVA (rMVA/Sg-E, rMVA/Sg-EM, 500 
rMVA/E and rMVA/EM), transfer plasmids were used to drive the homologous recombination. 501 
These transfer plasmids were constructed by cloning the different cDNAs for E glycoprotein in 502 
the pLW44 plasmid, resulting in plasmids pLW44/Sg-E, pLW44/Sg-EM, pLW44/E, 503 
pLW44/EM. Plasmids pLW44/Sg-E and pLW44/Sg-EM contain 80% E protein and its 504 
preceding signal sequence (Sg), whereas in pLW44/Sg-EM an undesired internal Kozak 505 
sequence was eliminated by mutation (M). Plasmids pLW44/E and pLW44/EM only contain 506 
80% E protein. Plasmid pLW44/EM also had the internal Kozak sequence mutated. (B) 507 
Representative scheme highlighting the Kozak sequences. Kozak sequences (in grey) are 508 
present in the start ATG (bold and underlined) and in a downstream ATG codon (only 509 
underlined). Plasmids pLW44/Sg-EM and pLW44/EM had this downstream Kozak sequence 510 
eliminated by mutation. Mutated bases are in bold and italic. (C) Western Blot analysis of C-511 
terminally truncated DENV-3 E protein expression in MVA-infected (1 PFU/cell) or control 512 
BHK21 cells as indicated above each lane. For each sample, lysates containing 30 µg of total 513 
protein extracts were separated on 12% polyacrylamide gels and western blots were probed 514 
with mouse anti-DENV 1+2+3+4 antibodies. Positive control (+ve) is DENV-3 E protein 515 
produced by E. coli. 516 
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TABLE 1 
Table 1. DENV-3E epitopes predicted. 2 
Namea Sequence MHC % IFN-γ+ (of CD8+)b 
D3E284-292 VGVGNRDFV H-2Db 0.27 
D3E313-321 TMAKNKPTL H-2Db - 
D3E365-375 EQDQNYVCKHT H-2Db - 
D3E369-377 NYVCKHTYV H-2Db/H-2Kd - 
D3E408-419 KVVQYENLKYTV H-2Db/H-2Kb 1.17 
D3E411-420 QYENLKYTVI H-2Kd/H-2Db - 
D3E416-423 KYTVIITV H-2Kd/H-2Db - 
D3E429-439 HQVGNETQGVT H-2Db - 
D3E443-453 TPQASTTEAIL H-2Ld - 
D3E463-471 CSPRTGLDF H-2Dd/H-2Ld - 
D3E489-496 QWFFDLPL H-2Db/H-2Kd - 
D3E540-548 TALTGATEI H-2Db/H-2Kd - 
D3E576-586 SYAMCTNTFVL H-2Kd - 
a Numbers in subscripts represent the amino acid positions in DENV-3 polyprotein 3 
(GenBank accession nº FJ850094). 4 
b Data are presented as means values from groups of 3 mice. 5 
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